Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
IQV - IQVIA Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$234.50
DETAILS
HIGH:
$287.00
LOW:
$185.00
MEDIAN:
$240.00
CONSENSUS:
$234.50
UPSIDE:
2.76%
Stock News
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last
IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.
Empowered Funds LLC Raises Holdings in IQVIA Holdings Inc. $IQV
Empowered Funds LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 147.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,519 shares of the medical research company's stock after acquiring an additional 11,642
Insider Selling: IQVIA (NYSE:IQV) Insider Sells $1,245,800.00 in Stock
IQVIA Holdings Inc. (NYSE: IQV - Get Free Report) insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company's stock,
An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know
The transaction involved the disposal of 558 shares at an exact weighted-average price of $245.21 per share on July 29, 2026. The sale reduced the insider's direct equity holdings by 16%, leaving 2,989 shares held directly.
An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know
The transaction involved the sale of 5,000 shares at $249.16 per share, representing a total value of about $1.2 million. This disposition resulted in a 19% reduction of the insider total direct equity holdings in the company.
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
The CEO of IQVIA executed an exercise-and-sell of stock appreciation rights involving shares at a weighted average price of $245.51 on July 29, 2026. Bousbib maintains substantial equity exposure through roughly 836,000 directly held shares and about 543,000 shares held indirectly via the Orohena Trust.
Amundi Has $148.20 Million Holdings in IQVIA Holdings Inc. $IQV
Amundi lowered its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 19.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 869,003 shares of the medical research company's stock after selling 206,218 shares during the period. Amundi owned 0.52% of IQVIA worth $148,200,000 as
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
IQVIA: A Great Business At The Wrong Price (Rating Downgrade)
IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.
IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings Inc. (IQV) Q2 2026 Earnings Call Transcript
IQVIA Holdings Inc. (IQV) Q2 2026 Earnings Call Transcript
IQVIA Q2 Earnings Call Highlights
IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share.
This Healthcare Stock Is Today's Best in the S&P 500
IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.
IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Beat Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.02 per share. This compares to earnings of $2.81 per share a year ago.
IQVIA raises annual profit forecast on clinical research demand
IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong demand for its healthcare data and analytics services, sending its shares up 11% before the bell.
IQVIA Reports Second-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2026. Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficien.
Castleark Management LLC Makes New Investment in IQVIA Holdings Inc. $IQV
Castleark Management LLC bought a new position in IQVIA Holdings Inc. (NYSE: IQV) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 22,580 shares of the medical research company's stock, valued at approximately $3,851,000. Several other hedge funds and other institutional investors also recently modified their
IQVIA Holdings Inc. $IQV Shares Sold by Dai ichi Life Insurance Company Ltd
Dai ichi Life Insurance Company Ltd decreased its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 34.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,723 shares of the medical research company's stock after selling 4,000 shares during the quarter. Dai ichi
Price Targets
Iqvia price target raised to $247 from $221 at RBC Capital
$247.00
(was $246.03)
RBC Capital
Iqvia price target raised to $270 from $210 at BMO Capital
$270.00
(was $249.51)
Sean Dodge
·
BMO Capital
Iqvia price target raised to $287 from $252 at Baird
$287.00
(was $243.31)
Eric Coldwell
·
Robert W. Baird
Iqvia price target raised to $230 from $215 at Mizuho
$230.00
(was $207.85)
Ann Hynes
·
Mizuho Securities
Iqvia named short-term buy idea at Deutsche Bank
$240.00
(was $208.00)
Deutsche Bank
Iqvia price target raised to $240 from $210 at HSBC
$240.00
(was $206.42)
Sidharth Sahoo
·
HSBC
Iqvia price target raised to $249 from $230 at Baird
$249.00
(was $193.22)
Robert W. Baird
Iqvia downgraded to Equal Weight from Overweight at Morgan Stanley
$200.00
(was $179.17)
Kallum Titchmarsh
·
Morgan Stanley
Iqvia price target lowered to $210 from $240 at HSBC
$210.00
(was $180.64)
HSBC
Iqvia price target lowered to $225 from $240 at Morgan Stanley
$225.00
(was $179.31)
Morgan Stanley
Iqvia price target lowered to $185 from $225 at Evercore ISI
$185.00
(was $172.54)
Elizabeth Anderson
·
Evercore ISI
Iqvia price target lowered to $215 from $266 at Mizuho
$215.00
(was $165.62)
Mizuho Securities
Iqvia price target lowered to $245 from $290 at Truist
$245.00
(was $165.64)
Truist Financial
Iqvia price target lowered to $240 from $265 at Morgan Stanley
$240.00
(was $178.88)
Morgan Stanley
Iqvia price target lowered to $240 from $280 at UBS
$240.00
(was $184.01)
UBS
Iqvia price target lowered to $250 from $260 at BMO Capital
$250.00
(was $184.75)
BMO Capital
Iqvia price target lowered to $220 from $273 at Stifel
$220.00
(was $184.67)
Stifel Nicolaus
Iqvia price target lowered to $210 from $230 at Barclays
$210.00
(was $180.96)
Luke Sergott
·
Barclays
IQVIA Holdings (IQV) PT Lowered to $225 at Evercore ISI
$225.00
(was $180.96)
Elizabeth Anderson
·
Evercore ISI
Iqvia price target raised to $266 from $250 at Mizuho
$266.00
(was $243.19)
Mizuho Securities